The redox-sensitive GSK3β is a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease.
Redox Biol.
2024 Mar 16;72:103127. doi: 10.1016/j.redox.2024.103127. [Epub ahead of print] PubMed PMID:
38527400; PubMed Central PMCID:
PMC10979123.
Negative Modulation of B Cell Activation by Melanocortin 1 Receptor Signaling Protects against Membranous Nephropathy.
J Am Soc Nephrol.
2023 Mar 1;34(3):467-481. doi: 10.1681/ASN.2022050605. Epub 2022 Nov 29. PubMed PMID:
36446431; PubMed Central PMCID:
PMC10103281.
Hematopoietic-specific melanocortin 1 receptor signaling protects against nephrotoxic serum nephritis and mediates the beneficial effect of melanocortin therapy.
Kidney Int.
2023 Feb;103(2):331-342. doi: 10.1016/j.kint.2022.09.025. Epub 2022 Oct 28. PubMed PMID:
36374665; PubMed Central PMCID:
PMC10431720.
Corrigendum to Fang Y, Chen B, Gong AY, et al. "The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults." Kidney Int. 2021;100:1037-1053.
Kidney Int.
2022 Jun;101(6):1301-1302. doi: 10.1016/j.kint.2022.04.002. PubMed PMID:
35597599; PubMed Central PMCID:
PMC9387735.
Age-related GSK3β overexpression drives podocyte senescence and glomerular aging.
J Clin Invest.
2022 Feb 15;132(4). doi: 10.1172/JCI141848. PubMed PMID:
35166234; PubMed Central PMCID:
PMC8843754.
The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults.
Kidney Int.
2021 Nov;100(5):1037-1053. doi: 10.1016/j.kint.2021.06.031. Epub 2021 Jul 8. PubMed PMID:
34246657; PubMed Central PMCID:
PMC8889914.
Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.
Front Endocrinol (Lausanne).
2021;12:749010. doi: 10.3389/fendo.2021.749010. eCollection 2021. Review. PubMed PMID:
34790170; PubMed Central PMCID:
PMC8591164.
Rationale and Design of Assessing the Effectiveness of Short-Term Low-Dose Lithium Therapy in Averting Cardiac Surgery-Associated Acute Kidney Injury: A Randomized, Double Blinded, Placebo Controlled Pilot Trial.
Front Med (Lausanne).
2021;8:639402. doi: 10.3389/fmed.2021.639402. eCollection 2021. PubMed PMID:
34195206; PubMed Central PMCID:
PMC8236527.
Permissive effect of GSK3β on profibrogenic plasticity of renal tubular cells in progressive chronic kidney disease.
Cell Death Dis.
2021 Apr 30;12(5):432. doi: 10.1038/s41419-021-03709-5. PubMed PMID:
33931588; PubMed Central PMCID:
PMC8087712.
Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities.
Front Physiol.
2021;12:651236. doi: 10.3389/fphys.2021.651236. eCollection 2021. Review. PubMed PMID:
33716796; PubMed Central PMCID:
PMC7943476.
Microdose Lithium Protects against Pancreatic Islet Destruction and Renal Impairment in Streptozotocin-Elicited Diabetes.
Antioxidants (Basel).
2021 Jan 19;10(1). doi: 10.3390/antiox10010138. PubMed PMID:
33478120; PubMed Central PMCID:
PMC7835906.
The ageing kidney: Molecular mechanisms and clinical implications.
Ageing Res Rev.
2020 Nov;63:101151. doi: 10.1016/j.arr.2020.101151. Epub 2020 Aug 22. Review. PubMed PMID:
32835891; PubMed Central PMCID:
PMC7595250.
Melanocortin 5 receptor signaling pathway in health and disease.
Cell Mol Life Sci.
2020 Oct;77(19):3831-3840. doi: 10.1007/s00018-020-03511-0. Epub 2020 Apr 4. Review. PubMed PMID:
32248247; PubMed Central PMCID:
PMC7511443.
RNA-binding proteins tristetraprolin and human antigen R are novel modulators of podocyte injury in diabetic kidney disease.
Cell Death Dis.
2020 Jun 2;11(6):413. doi: 10.1038/s41419-020-2630-x. PubMed PMID:
32487989; PubMed Central PMCID:
PMC7265504.
Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling.
Clin Sci (Lond).
2020 Apr 17;134(7):695-710. doi: 10.1042/CS20200016. PubMed PMID:
32167144; PubMed Central PMCID:
PMC9870294.
Relapse of Nephrotic Syndrome after Adrenocorticotropic Hormone-Induced Remission: Implications of Adrenocorticotropic Hormone Antibodies.
Am J Nephrol.
2020;51(5):390-394. doi: 10.1159/000506854. Epub 2020 Mar 18. PubMed PMID:
32187600; PubMed Central PMCID:
PMC7521046.
Triptolide potentiates the cytoskeleton-stabilizing activity of cyclosporine A in glomerular podocytes via a GSK3β dependent mechanism.
Am J Transl Res.
2020;12(3):800-812. eCollection 2020. PubMed PMID:
32269713; PubMed Central PMCID:
PMC7137037.
Glycogen synthase kinase 3β hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease.
Kidney Int.
2020 Jan;97(1):175-192. doi: 10.1016/j.kint.2019.08.036. Epub 2019 Oct 10. PubMed PMID:
31791666.
Lithium targeting of AMPK protects against cisplatin-induced acute kidney injury by enhancing autophagy in renal proximal tubular epithelial cells.
FASEB J.
2019 Dec;33(12):14370-14381. doi: 10.1096/fj.201901712R. Epub 2019 Oct 29. PubMed PMID:
31661633.
GSK3β-mediated Keap1-independent regulation of Nrf2 antioxidant response: A molecular rheostat of acute kidney injury to chronic kidney disease transition.
Redox Biol.
2019 Sep;26:101275. doi: 10.1016/j.redox.2019.101275. Epub 2019 Jul 17. PubMed PMID:
31349118; PubMed Central PMCID:
PMC6669347.
Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease.
Clin Sci (Lond).
2019 Jun 28;133(12):1321-1339. doi: 10.1042/CS20190372. Print 2019 Jun 28. Review. PubMed PMID:
31221822.
Mineralocorticoid receptor: A hidden culprit for hemodialysis vascular access dysfunction.
EBioMedicine.
2019 Jan;39:621-627. doi: 10.1016/j.ebiom.2018.11.054. Epub 2018 Dec 5. Review. PubMed PMID:
30527626; PubMed Central PMCID:
PMC6354623.
Targeting Regulatory T Cells for Transplant Tolerance: New Insights and Future Perspectives.
Kidney Dis (Basel).
2018 Nov;4(4):205-213. doi: 10.1159/000490703. Epub 2018 Jul 31. Review. PubMed PMID:
30574497; PubMed Central PMCID:
PMC6276757.
Blocking Macrophage Migration Inhibitory Factor Protects Against Cisplatin-Induced Acute Kidney Injury in Mice.
Mol Ther.
2018 Oct 3;26(10):2523-2532. doi: 10.1016/j.ymthe.2018.07.014. Epub 2018 Jul 17. PubMed PMID:
30077612; PubMed Central PMCID:
PMC6171075.
Ecdysone Elicits Chronic Renal Impairment via Mineralocorticoid-Like Pathogenic Activities.
Cell Physiol Biochem.
2018;49(4):1633-1645. doi: 10.1159/000493499. Epub 2018 Sep 18. PubMed PMID:
30227391; PubMed Central PMCID:
PMC10317082.
Activation of mineralocorticoid receptor by ecdysone, an adaptogenic and anabolic ecdysteroid, promotes glomerular injury and proteinuria involving overactive GSK3β pathway signaling.
Sci Rep.
2018 Aug 15;8(1):12225. doi: 10.1038/s41598-018-29483-7. PubMed PMID:
30111886; PubMed Central PMCID:
PMC6093907.
Effectiveness and Safety of Peritoneal Dialysis Treatment in Patients with Refractory Congestive Heart Failure due to Chronic Cardiorenal Syndrome.
Biomed Res Int.
2018;2018:6529283. doi: 10.1155/2018/6529283. eCollection 2018. PubMed PMID:
29888270; PubMed Central PMCID:
PMC5985089.
Valproate hampers podocyte acquisition of immune phenotypes via intercepting the GSK3β facilitated NFkB activation.
Oncotarget.
2017 Oct 24;8(51):88332-88344. doi: 10.18632/oncotarget.19917. eCollection 2017 Oct 24. PubMed PMID:
29179438; PubMed Central PMCID:
PMC5687608.
Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody.
Pediatrics.
2017 Jul;140(1). doi: 10.1542/peds.2016-2169. PubMed PMID:
28642375; PubMed Central PMCID:
PMC5495526.
What we need to know about the effect of lithium on the kidney.
Am J Physiol Renal Physiol.
2016 Dec 1;311(6):F1168-F1171. doi: 10.1152/ajprenal.00145.2016. Epub 2016 Apr 27. Review. PubMed PMID:
27122541; PubMed Central PMCID:
PMC5210210.
Rescue therapy with Tanshinone IIA hinders transition of acute kidney injury to chronic kidney disease via targeting GSK3β.
Sci Rep.
2016 Nov 18;6:36698. doi: 10.1038/srep36698. PubMed PMID:
27857162; PubMed Central PMCID:
PMC5114614.
Activation of FXR protects against renal fibrosis via suppressing Smad3 expression.
Sci Rep.
2016 Nov 17;6:37234. doi: 10.1038/srep37234. PubMed PMID:
27853248; PubMed Central PMCID:
PMC5112546.
Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3β Reinforces the Nrf2 Antioxidant Defense against Podocytopathy.
J Am Soc Nephrol.
2016 Aug;27(8):2289-308. doi: 10.1681/ASN.2015050565. Epub 2015 Dec 8. PubMed PMID:
26647425; PubMed Central PMCID:
PMC4978041.
Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression.
J Am Soc Nephrol.
2016 Jul;27(7):2092-108. doi: 10.1681/ASN.2015040457. Epub 2015 Dec 23. PubMed PMID:
26701983; PubMed Central PMCID:
PMC4926973.
MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.
Sci Rep.
2016 Jun 8;6:27589. doi: 10.1038/srep27589. PubMed PMID:
27270328; PubMed Central PMCID:
PMC4897792.
The β isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy.
J Pathol.
2016 May;239(1):23-35. doi: 10.1002/path.4692. Epub 2016 Mar 16. PubMed PMID:
26876299; PubMed Central PMCID:
PMC4833638.
Tanshinone IIA Attenuates Renal Fibrosis after Acute Kidney Injury in a Mouse Model through Inhibition of Fibrocytes Recruitment.
Biomed Res Int.
2015;2015:867140. doi: 10.1155/2015/867140. Epub 2015 Dec 29. PubMed PMID:
26885500; PubMed Central PMCID:
PMC4739267.
The redox sensitive glycogen synthase kinase 3β suppresses the self-protective antioxidant response in podocytes upon oxidative glomerular injury.
Oncotarget.
2015 Nov 24;6(37):39493-506. doi: 10.18632/oncotarget.6303. PubMed PMID:
26567873; PubMed Central PMCID:
PMC4741841.
Remote ischemic preconditioning for kidney protection: GSK3β-centric insights into the mechanism of action.
Am J Kidney Dis.
2015 Nov;66(5):846-56. doi: 10.1053/j.ajkd.2015.06.026. Epub 2015 Aug 10. Review. PubMed PMID:
26271146; PubMed Central PMCID:
PMC4623948.
Fine-tuning of NFκB by glycogen synthase kinase 3β directs the fate of glomerular podocytes upon injury.
Kidney Int.
2015 Jun;87(6):1176-90. doi: 10.1038/ki.2014.428. Epub 2015 Jan 28. PubMed PMID:
25629551; PubMed Central PMCID:
PMC4449834.
Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.
Clin Sci (Lond).
2015 May;128(9):527-35. doi: 10.1042/CS20140432. Review. PubMed PMID:
25671776; PubMed Central PMCID:
PMC4356246.
P2X7 receptor inhibition protects against ischemic acute kidney injury in mice.
Am J Physiol Cell Physiol.
2015 Mar 15;308(6):C463-72. doi: 10.1152/ajpcell.00245.2014. Epub 2015 Jan 14. PubMed PMID:
25588875; PubMed Central PMCID:
PMC4360025.
Pharmacological targeting of GSK3β confers protection against podocytopathy and proteinuria by desensitizing mitochondrial permeability transition.
Br J Pharmacol.
2015 Feb;172(3):895-909. doi: 10.1111/bph.12952. Epub 2014 Dec 15. PubMed PMID:
25262943; PubMed Central PMCID:
PMC4301697.
Glycogen synthase kinase 3β orchestrates microtubule remodeling in compensatory glomerular adaptation to podocyte depletion.
J Biol Chem.
2015 Jan 16;290(3):1348-63. doi: 10.1074/jbc.M114.593830. Epub 2014 Dec 2. PubMed PMID:
25468908; PubMed Central PMCID:
PMC4340382.
Therapeutic targeting of GSK3β enhances the Nrf2 antioxidant response and confers hepatic cytoprotection in hepatitis C.
Gut.
2015 Jan;64(1):168-79. doi: 10.1136/gutjnl-2013-306043. Epub 2014 May 8. PubMed PMID:
24811996; PubMed Central PMCID:
PMC4263291.
Glycogen synthase kinase 3β dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: implications for the protective effect of low-dose lithium in podocytopathy.
Am J Pathol.
2014 Oct;184(10):2742-56. doi: 10.1016/j.ajpath.2014.06.027. PubMed PMID:
25239564; PubMed Central PMCID:
PMC4188873.
Class I HDAC activity is required for renal protection and regeneration after acute kidney injury.
Am J Physiol Renal Physiol.
2014 Aug 1;307(3):F303-16. doi: 10.1152/ajprenal.00102.2014. Epub 2014 May 7. PubMed PMID:
24808536; PubMed Central PMCID:
PMC4121572.
Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy.
J Pharmacol Exp Ther.
2014 Aug;350(2):243-56. doi: 10.1124/jpet.113.212076. Epub 2014 May 15. PubMed PMID:
24833701; PubMed Central PMCID:
PMC4109489.
Gene therapy with biosynthetic nanoscale peptide Cecropin A driven by the survivin promoter for hepatocarcinoma cells.
J Biomed Nanotechnol.
2014 Jul;10(7):1391-9. doi: 10.1166/jbn.2014.1891. PubMed PMID:
24804559.
Inhibitory effect of biosynthetic nanoscale peptide Melittin on hepatocellular carcinoma, driven by survivin promoter.
J Biomed Nanotechnol.
2014 Apr;10(4):695-706. doi: 10.1166/jbn.2014.1830. PubMed PMID:
24734522.
What would you like to do?